Should You Buy Integer Holdings Corp (ITGR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
86.860
1 Day change
0.45%
52 Week Range
144.760
Analysis Updated At
2026/01/29
ITGR is not a good buy right now for an impatient investor. The stock has a modestly bullish call-skew in options and solid Q3’25 growth, but near-term risk is dominated by negative technical momentum (MACD turning down into resistance) and an escalating lawsuit/news overhang ahead of the next earnings catalyst (2026-02-19). With no Intellectia buy signals today, the risk/reward is not compelling enough to chase at ~$86.5; this is a HOLD/avoid-new-entry setup until price reclaims resistance with improving momentum.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.0997) and negatively expanding, signaling weakening momentum despite price holding near recent levels. RSI(6)=66.6 is near the upper end of neutral (not overbought), which often means there’s room to move but momentum is currently fading.
Moving averages: Converging MAs suggest consolidation/range behavior rather than a clean uptrend.
Key levels: Pivot ~85.67. Immediate resistance R1 ~87.31 (then R2 ~88.33). Support S1 ~84.03 (then S2 ~83.02). At $86.47, ITGR is closer to resistance than support, so upside is capped unless it breaks/holds above ~87.3.
Pattern-based near-term odds (provided): ~50% chance of ~+1.3% next day; this implies limited edge and no strong directional conviction.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment/positioning: Very low put/call ratios (OI PCR 0.31; volume PCR 0.06) indicate bullish positioning (call-heavy) and limited near-term demand for downside hedges.
Activity: Today’s option volume (217) is ~24.8x the 30-day average, showing a sentiment/catalyst-driven surge in attention.
Volatility: IV 30d ~47.2 with IV percentile ~95.6 (very elevated vs its recent history), implying the market is pricing higher uncertainty; this often happens around event risk (earnings, legal headlines). Elevated IV can amplify stock swings and makes “buying upside” via options more expensive.
Technical Summary
Sell
4
Buy
7
Positive Catalysts
- Activist involvement (Irenic Capital reported sub-3% stake) raises the probability of board refresh/strategic review; a sale process could re-rate shares above current levels.
- Next earnings: QDEC 2025 results on 2026-02-19 (pre-market), with Street EPS est. ~1.70—potential catalyst if guidance and medical-device demand trends stabilize.
- Options market positioning is notably bullish (call-skew) which can support rallies if news flow improves.
Neutral/Negative Catalysts
- Multiple late-January legal headlines: class action and fiduciary duty investigations tied to alleged misstatements and the prior sales guidance cut; this is a near-term sentiment overhang.
- Technical momentum is deteriorating (MACD negative and expanding) while price sits just below resistance (~87.3), increasing the odds of a pullback toward ~84 if sellers press.
- Elevated implied volatility suggests the market expects sharper moves; downside reactions to headlines/earnings could be swift.
Financial Performance
Latest quarter: 2025/Q3.
Growth trends: Revenue $467.7M (+8.41% YoY), Net Income $39.7M (+11.96% YoY), EPS $1.11 (+12.12% YoY). Profitability improved with Gross Margin 27.46% (+0.88 pts YoY). Overall, Q3 showed healthy top-line growth and faster earnings growth, consistent with operating leverage, but the market is currently more focused on forward sales/guidance credibility given the legal/news backdrop.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Generally constructive but mixed. Truist remains Buy and raised its PT to $95 (from $86) on 2025-12-18 after previously cutting PT slightly in late Nov; Raymond James reiterated Outperform and highlighted activist-driven strategic alternatives; Citi stayed Neutral with PT whipsawing down (to $69 on 2025-11-03) and then up (to $75 on 2025-12-11).
Wall Street pros: Potential undervaluation, activist/strategic optionality, and multi-quarter catalysts for revenue acceleration into FY26.
Wall Street cons: Near-term drags and the need for a clearer re-acceleration path; Neutral stance from Citi suggests valuation/upside may be less clear without execution and cleaner guidance.
Politicians/Influential trading: No recent congress trading data available; hedge funds and insiders show no significant recent trends (both neutral).
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 86.470
Low
75
Averages
93.38
High
140
Current: 86.470
Low
75
Averages
93.38
High
140
Truist
Richard Newitter
Buy
maintain
$86 -> $95
AI Analysis
2025-12-18
Reason
Truist
Richard Newitter
Price Target
$86 -> $95
AI Analysis
2025-12-18
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Integer to $95 from $86 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
Raymond James
Outperform
maintain
2025-12-18
Reason
Raymond James
Price Target
2025-12-18
maintain
Outperform
Reason
Raymond James notes that Wednesday evening, the Wall Street Journal reported that Irenic Capital Management has taken a sub-3% position and activist approach to Integer, including a private letter to the board earlier this week. The report states an intent to push for a board refresh and potential sale under the belief that public markets undervalue the company. The firm's conversations confirm these central tenets. Raymond agrees that the current valuation underappreciates Integer's assets. The firm ultimately thinks the stock can perform as a public equity as the current drags abate. However, a sale would likely draw interest at valuations above current trading levels and could offer a more immediate path to upside, it argues. Regardless of a transaction, Raymond sees room for equity holders to be rewarded over time. The firm has an Outperform rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ITGR
